These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8098029)

  • 21. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection.
    Margolick JB; Muñoz A; Vlahov D; Solomon L; Astemborski J; Cohn S; Nelson KE
    JAMA; 1992 Mar; 267(12):1631-6. PubMed ID: 1347321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle.
    Cordaro JA; Morse GD; Bartos L; Gugino LJ; Maliszewski M; Colomaio R; Shelton M; O'Donnell A; Hewitt R
    Pharmacotherapy; 1993; 13(4):369-77. PubMed ID: 8361863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability of cefuroxime axetil: comparison of standard and abbreviated methods.
    Lang CC; Moreland TA; Davey PG
    J Antimicrob Chemother; 1990 Apr; 25(4):645-50. PubMed ID: 2351625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Porphyrin abnormalities in acquired immunodeficiency syndrome.
    O'Connor WJ; Murphy GM; Darby C; Fogarty J; Mulcahy F; O'Moore R; Barnes L
    Arch Dermatol; 1996 Dec; 132(12):1443-7. PubMed ID: 8961872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
    Brockmeyer NH; Tillmann I; Mertins L; Barthel B; Goos M
    Eur J Med Res; 1997 Sep; 2(9):377-83. PubMed ID: 9300934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of zidovudine in infants: a population analysis across studies.
    Mirochnick M; Capparelli E; Connor J
    Clin Pharmacol Ther; 1999 Jul; 66(1):16-24. PubMed ID: 10430105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.
    Barry M; Howe JL; Back DJ; Swart AM; Breckenridge AM; Weller IV; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 Jan; 37(1):7-12. PubMed ID: 8148221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy with zidovudine, recombinant granulocyte colony stimulating factors and erythropoietin in asymptomatic HIV patients.
    Perrella O; Finelli E; Perrella A; Tartaglia G; Scognamiglio P; Scalera G
    J Chemother; 1996 Feb; 8(1):63-6. PubMed ID: 8835112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
    Barry M; Gibbons S; Back D; Mulcahy F
    Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients.
    Gallicano K; Sahai J; Ormsby E; Cameron DW; Pakuts A; McGilveray I
    Br J Clin Pharmacol; 1993 Aug; 36(2):128-31. PubMed ID: 8398581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
    AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologic response to a protein, carbohydrate, fat meal in patients with human immunodeficiency virus who underwent small intestinal enteropathy as characterized by a kinetic model of D-xylose absorption.
    Carlson SJ; Deutsch JC; Craig RM
    JPEN J Parenter Enteral Nutr; 1998; 22(1):27-30. PubMed ID: 9437651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis.
    Kremer D; Munar MY; Kohlhepp SJ; Swan SK; Stinnett EA; Gilbert DN; Young EW; Bennett WM
    Pharmacotherapy; 1992; 12(1):56-60. PubMed ID: 1549540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons.
    Griffy KG
    AIDS; 1996 Dec; 10 Suppl 4():S3-6. PubMed ID: 9110063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zidovudine response relationships in early human immunodeficiency virus infection.
    Sale M; Sheiner LB; Volberding P; Blaschke TF
    Clin Pharmacol Ther; 1993 Nov; 54(5):556-66. PubMed ID: 7900949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers.
    Chompootaweep S; Poonsrisawat J; Xumseang P
    J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S79-85. PubMed ID: 17722305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of zidovudine. An update.
    Acosta EP; Page LM; Fletcher CV
    Clin Pharmacokinet; 1996 Apr; 30(4):251-62. PubMed ID: 8983858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.